Comparing the efficacy of nebulizer recombinant human DNase and hypertonic saline as monotherapy and combined treatment in the treatment of persistent atelectasis in mechanically ventilated newborns

Pediatrics International

Volumn 54, Issue 1, 2012, Pages 131-136

  Altunhan, Hüseyin ^a   Annagür, Ali ^a   Pekcan, Sevgi ^a   Örs, Rahmi ^a   Koç, Hasan ^a  

^a SELCUK UNIVERSITY   (Turkey)

Author keywords

atelectasis; dornase alfa; hypertonic saline; newborn; recombinant human DNase

Indexed keywords

CARBON DIOXIDE; DORNASE ALFA; SODIUM CHLORIDE;

ARTICLE; ARTIFICIAL VENTILATION; ATELECTASIS; BLOOD CARBON DIOXIDE TENSION; BLOOD GAS PARAMETERS; BREATHING RATE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; FEMALE; FRACTION OF INSPIRED OXYGEN; HEALING; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL NEBULIZER; MONOTHERAPY; NEWBORN; PRIORITY JOURNAL; X RAY;

COMBINED MODALITY THERAPY; DEOXYRIBONUCLEASE I; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEBULIZERS AND VAPORIZERS; PULMONARY ATELECTASIS; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; SALINE SOLUTION, HYPERTONIC; TREATMENT OUTCOME;

EID: 84857204324     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/j.1442-200X.2011.03519.x     Document Type: Article

References (39)

1. Hendriks T, de Hoog M, Lequin MH, et al,. DNase and atelectasis in non-cystic fibrosis pediatric patients. Crit. Care 2005; 9: 351-6.
2. Riethmueller J, Kumpf M, Borth-Bruhns T, et al,. Clinical and in vitro effect of dornase alfa in mechanically ventilated pediatric non-cystic fibrosis patients with atelectases. Cell. Physiol. Biochem. 2009; 23: 205-10.
3. Peroni DG, Boner AL,. Atelectasis: mechanisms, diagnosis and management. Paediatr. Respir. Rev. 2000; 1: 274-8.
4. Bloomfield FH, Teele RL, Voss M, et al,. Inter- and intra-observer variability in the assessment of atelectasis and consolidation in neonatal chest radiographs. Pediatr. Radiol. 1999; 29: 459-62. (Pubitemid 29257677)
5. Van Kaam AH, Lachmann RA, Herting E, et al,. Reducing atelectasis attenuates bacterial growth and translocation in experimental pneumonia. Am. J. Respir. Crit. Care Med. 2004; 169: 1046-53. (Pubitemid 38543645)
6. Bye PT, Elkins MR,. Other mucoactive agents for cystic fibrosis. Paediatr. Respir. Rev. 2007; 8: 30-9. (Pubitemid 46523788)
7. Erdeve O, Uras N, Atasay B, et al,. Efficacy and safety of nebulized recombinant human DNase as rescue treatment for persistent atelectasis in newborns: case-series. Croat. Med. J. 2007; 48: 234-9. (Pubitemid 46651030)
8. Touleimat BA, Conoscenti CS, Fine JM,. Recombinant human DNase in management of lobar atelectasis due to retained secretions. Thorax 1995; 50: 1319-21.
9. Riethmueller J, Borth-Bruhns T, Kumpf M, et al,. Recombinant human deoxyribonuclease shortens ventilation time in young, mechanically ventilated children. Pediatr. Pulmonol. 2006; 41: 61-6. (Pubitemid 43117369)
10. Merkus PJ, de Hoog M, van Gent R, et al,. DNase treatment for atelectasis in infants with severe respiratory syncytial virus bronchiolitis. Eur. Respir. J. 2001; 18: 734-7. (Pubitemid 33040634)
11. Schindler MB,. Treatment of atelectasis: where is the evidence? Crit. Care 2005; 9: 341-2. (Pubitemid 41136274)
12. Suri R, Grieve R, Normand C, et al,. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax 2002; 57: 841-6. (Pubitemid 35178606)
13. Suri R, Metcalfe C, Lees B, et al,. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet 2001; 358: 1316-21. (Pubitemid 33016495)
14. Fitzgerald DA, Hilton J, Jepson B, et al,. A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics 2005; 116: 549-54.
15. Suri R, Marshall LJ, Wallis C, et al,. Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2002; 166: 352-5. (Pubitemid 34864425)
16. Nasr SZ, Strouse PJ, Soskolne E, et al,. Efficacy of recombinant human deoxyribonuclease I in the hospital management of respiratory syncytial virus bronchiolitis. Chest 2001; 120: 203-8. (Pubitemid 32744880)
17. Küpeli S, Teksam O, Dogru D, et al,. Use of recombinant human DNase in a premature infant with recurrent atelectasis. Pediatr. Int. 2003; 45: 584-6. (Pubitemid 37430764)
18. El Hassan NO, Chess PR, Huysman MW, et al,. Rescue use of DNase in critical lung atelectasis and mucus retention in premature neonates. Pediatrics 2001; 108: 468-70.
19. Reiter PD, Townsend SF, Velasquez R,. Dornase alfa in premature infants with severe respiratory distress and early bronchopulmonary dysplasia. J. Perinatol. 2000; 20: 530-4.
20. Mandelberg A, Tal G, Witzling M, et al,. Nebulized 3% hypertonic saline solution treatment in hospitalized infants with viral bronchiolitis. Chest 2003; 123: 481-7. (Pubitemid 36269434)
21. Kuzik BA, Al-Qadhi SA, Kent S, et al,. Nebulized hypertonic saline in the treatment of viral bronchiolitis in infants. J. Pediatr. 2007; 151: 266-70.
22. Ballmann M, von der Hardt H,. Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. J. Cyst. Fibros. 2002; 1: 35-7.
23. Suri R, Metcalfe C, Wallis C, et al,. Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis. Pediatr. Pulmonol. 2004; 37: 305-10. (Pubitemid 38523942)
24. Nasr SZ, Kuhns LR, Brown RW, et al,. Use of computerized tomography and chest x-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study. Pediatr. Pulmonol. 2001; 31: 377-82. (Pubitemid 32417256)
25. Babcook CJ, Norman GR, Coblentz CL,. Effect of clinical history on the interpretation of chest radiographs in childhood bronchiolitis. Invest. Radiol. 1993; 28: 214-17. (Pubitemid 23163266)
26. Shak S, Capon DJ, Hellmiss R, et al,. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc. Natl. Acad. Sci. U. S. A. 1990; 87: 9188-92. (Pubitemid 120030590)
27. Aitken ML, Burke W, McDonald G, et al,. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study. JAMA 1992; 267: 1947-51.
28. Greally P,. Human recombinant DNase for mucus plugging in status asthmaticus. Lancet 1995; 346: 1423-4.
29. Ten Berge M, Brinkhorst G, Kroon AA, et al,. DNase treatment in primary ciliary dyskinesia-assessment by nocturnal pulse oximetry. Pediatr. Pulmonol. 1999; 27: 59-61. (Pubitemid 29063803)
30. Tatli MM, Kumral A, Duman N, et al,. Pulmonary hemorrhage after rhDNase treatment in a preterm infant with chronic lung disease. Int. Pediatr. 2004; 19: 234-6. (Pubitemid 39665586)
31. Boeuf B, Prouix F, Morneau S, et al,. Safety of endotracheal rh DNAse (Pulmozyme) for treatment of pulmonary atelectasis in mechanically ventilated children. Pediatr. Pulmonol. 1998; 26: 147. (Pubitemid 28381480)
32. King M, Dasgupta B, Tomkiewicz RP, et al,. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I. Am. J. Respir. Crit. Care Med. 1997; 156: 173-7. (Pubitemid 27293184)
33. Angle N, Hoyt DB, Coimbra R, et al,. Hypertonic saline resuscitation diminishes lung injury by suppressing neutrophil activation after hemorrhagic shock. Shock 1998; 9: 164-70. (Pubitemid 128463280)
34. Murao Y, Hoyt DB, Loomis W, et al,. Does the timing of hypertonic saline resuscitation affect its potential to prevent lung damage? Shock 2000; 14: 18-23.
35. Cataldo D, Foidart JM, Lau L, et al,. Induced sputum: comparison between isotonic and hypertonic saline solution inhalation in patients with asthma. Chest 2001; 120: 1815-21. (Pubitemid 34053439)
36. Eng PA, Morton J, Douglass JA, et al,. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr. Pulmonol. 1996; 21: 77-83. (Pubitemid 26098513)
37. Araki H, Sly PD,. Inhalation of hypertonic saline as a bronchial challenge in children with mild asthma and normal children. J. Allergy Clin. Immunol. 1989; 84: 99-107. (Pubitemid 19188996)
38. Williams PV,. Inhalation bronchoprovocation in children. Immunol. Clin. North Am. 1998; 18: 149-64. (Pubitemid 28108112)
39. Robinson M, Hemming AL, Regnis JA, et al,. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997; 52: 900-3. (Pubitemid 27473934)